Literature DB >> 12799138

TIGR is upregulated in the chronic glial scar in response to central nervous system injury and inhibits neurite outgrowth.

Michael J Jurynec1, Catherine P Riley, Deepak K Gupta, Thai D Nguyen, Robert J McKeon, Charles R Buck.   

Abstract

Reactive astrocytes respond to central nervous system (CNS) injury and disease by elaborating a glial scar that is inhibitory to axonal regeneration. To identify genes that may be involved in the astrocytic response to injury, we used differential display polymerase chain reaction and an in vivo model of the CNS glial scar. Expression of the trabecular meshwork inducible glucocorticoid response (TIGR) gene was increased in gliotic tissue compared with the uninjured cerebral cortex. Increased TIGR expression by reactive astrocytes was confirmed by in situ hybridization, quantitative reverse transcriptase-polymerase chain reaction, immunoblot analysis, and immunohistochemistry. Although mutations of the TIGR gene have been implicated in glaucoma, a function for TIGR has not been reported. Since TIGR is secreted, we assessed a possible role in inhibition of neuronal regeneration with an in vitro bioassay and found that this protein is a potent inhibitor of neurite outgrowth. Thus, TIGR is a newly identified component of the CNS glial scar that is likely to contribute to neuronal regenerative failure characteristic of the mammalian CNS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12799138     DOI: 10.1016/s1044-7431(03)00019-8

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  16 in total

1.  Interaction of myocilin with gamma-synuclein affects its secretion and aggregation.

Authors:  Irina Surgucheva; Bum-Chan Park; Beatrice Y J T Yue; Stanislav Tomarev; Andrei Surguchov
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

2.  Improvement of cerebral function by anti-amyloid precursor protein antibody infusion after traumatic brain injury in rats.

Authors:  Tatsuki Itoh; Takao Satou; Shozo Nishida; Masahiro Tsubaki; Shigeo Hashimoto; Hiroyuki Ito
Journal:  Mol Cell Biochem       Date:  2009-01-07       Impact factor: 3.396

3.  Neural stem cells and new neurons in the cerebral cortex of stroke-prone spontaneously hypertensive rats after stroke.

Authors:  Tatsuki Itoh; Takao Satou; Kumiko Takemori; Shigeo Hashimoto; Hiroyuki Ito
Journal:  J Mol Neurosci       Date:  2009-08-11       Impact factor: 3.444

Review 4.  Glaucoma-associated myocilin: a better understanding but much more to learn.

Authors:  Zachary T Resch; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-08-29       Impact factor: 3.467

5.  Cultured rat astrocytes give rise to neural stem cells.

Authors:  Tatsuki Itoh; Takao Satou; Shozo Nishida; Shigeo Hashimoto; Hiroyuki Ito
Journal:  Neurochem Res       Date:  2006-10-20       Impact factor: 3.996

6.  Myocilin, a glaucoma-associated protein, promotes cell migration through activation of integrin-focal adhesion kinase-serine/threonine kinase signaling pathway.

Authors:  Heung Sun Kwon; Stanislav I Tomarev
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

7.  Differential effects of myocilin and optineurin, two glaucoma genes, on neurite outgrowth.

Authors:  Takahisa Koga; Xiang Shen; Jeong-Seok Park; Ye Qiu; Bum-Chan Park; Rajalekshmy Shyam; Beatrice Y J T Yue
Journal:  Am J Pathol       Date:  2009-12-03       Impact factor: 4.307

Review 8.  Molecular complexity of primary open angle glaucoma: current concepts.

Authors:  Kunal Ray; Suddhasil Mookherjee
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

9.  Suppression of keratoepithelin and myocilin by small interfering RNA (an American Ophthalmological Society thesis).

Authors:  Andrew J W Huang
Journal:  Trans Am Ophthalmol Soc       Date:  2007

10.  The expression of myocilin during murine eye development.

Authors:  Carmen Knaupp; Cassandra Flügel-Koch; Andreas Goldwich; Andreas Ohlmann; Ernst R Tamm
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-01-29       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.